Literature DB >> 24411992

Indication for and extension of pelvic lymph node dissection during robot-assisted radical prostatectomy: an analysis of five European institutions.

Nazareno Suardi1, Alessandro Larcher2, Alexander Haese3, Vincenzo Ficarra4, Alexander Govorov5, Nicolò M Buffi2, Jochen Walz6, Bernardo Rocco7, Marco Borghesi8, Thomas Steuber3, Giovannalberto Pini9, Alberto Briganti2, Alexander M Mottrie8, Giorgio Guazzoni2, Francesco Montorsi2, Dmitry Pushkar5, Henk Van Der Poel10.   

Abstract

BACKGROUND: Several reports have shown that patients who undergo minimally invasive radical prostatectomy have a lower chance of undergoing pelvic lymph node dissection (PLND), irrespective of the disease characteristics.
OBJECTIVE: We evaluated the rate and extension of PLND in patients who underwent robot-assisted radical prostatectomy (RARP). We tested the adherence of the indication for PLND to the European Association of Urology (EAU) guidelines. DESIGN, SETTING, AND PARTICIPANTS: Our study was a multi-institutional retrospective analysis of prospectively collected data on 2985 consecutive patients who underwent RARP at five high-volume European institutions. Patients were stratified according to preoperative cancer risk group. INTERVENTION: RARP. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The rate and extent of PLND across different institutions were analyzed. Univariable and multivariable logistic regression models evaluated the association between preoperative variables and the probability of receiving PLND, as well as the presence of lymph node invasion (LNI). Finally, the probability of LNI was calculated for each patient, and the indication for PLND was compared with the EAU guidelines' indications. RESULTS AND LIMITATIONS: A lymph node dissection was performed in 1777 patients (59.7%; 34.5% of low-risk patients, 64.9% of intermediate-risk patients, and 91.2% of high-risk patients). These rates were different across institutions: 5.0-41.4% in low-risk patients (p<0.001), 31.3-81.4% in intermediate-risk patients (p<0.001), and 84.6-96.4% in high-risk patients (p=0.06). The mean and median number of nodes removed was 10.8, and 122 patients (4.1%) had nodal metastases. At multivariable analysis, the institution represented an independent predictor of PLND (p<0.001). Of patients with current indication for PLND (EAU guidelines), 77.8% actually received the procedure. Limitations were the retrospective study design with different pathologic assessment and lack of follow-up data.
CONCLUSIONS: PLND is performed in a high proportion of patients undergoing RARP in high-volume centers in Europe for whom the procedure is indicated by the EAU guidelines, but significant differences exist among institutions. An effort toward a more rigorous standardization of PLND is advocated. PATIENT
SUMMARY: In this paper, we investigated the indication for and extension of pelvic lymph node dissection (PLND) in different institutions in Europe. Despite PLND being widely performed, significant variations with regard to PLND do exist among different institutions. Therefore, a thrust toward more rigorous attention to PLND is advocated.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph nodes; Lymphadenectomy; Prostate cancer; Radical prostatectomy; Robotics

Mesh:

Year:  2014        PMID: 24411992     DOI: 10.1016/j.eururo.2013.12.059

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes.

Authors:  John T Miura; Lesly A Dossett; Ram Thapa; Youngchul Kim; Aishwarya Potdar; Hala Daou; James Sun; Amod A Sarnaik; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2019-04-04       Impact factor: 5.344

2.  Multicenter evaluation of guideline adherence for pelvic lymph node dissection in patients undergoing open retropubic vs. laparoscopic or robot assisted radical prostatectomy according to the recent German S3 guideline on prostate cancer.

Authors:  Angelika Borkowetz; Johannes Bruendl; Martin Drerup; Jonas Herrmann; Hendrik Isbarn; Burkhard Beyer
Journal:  World J Urol       Date:  2018-02-09       Impact factor: 4.226

3.  Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan.

Authors:  Shuichi Morizane; Masashi Honda; Satoshi Fukasawa; Atsushi Komaru; Junichi Inokuchi; Masatoshi Eto; Masaki Shimbo; Kazunori Hattori; Yoshiaki Kawano; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2017-12-11       Impact factor: 3.402

4.  Comparison of nomograms predicting lymph node invasion in patients undergoing radical prostatectomy for prostate cancer.

Authors:  G J Nason; E M O'Connor; D MacMahon; B Moss; S W Considine; A Cahill; C O'Rourke; F M O'Brien
Journal:  Ir J Med Sci       Date:  2017-05-06       Impact factor: 1.568

Review 5.  Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer.

Authors:  Michele Colicchia; Vidit Sharma; Firas Abdollah; Alberto Briganti; R Jeffrey Karnes
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

6.  Positive Association between Preoperative Total Testosterone and Lymph Node Invasion in Intermediate Risk Prostate Cancer.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Paolo Corsi; Tania Processali; Marco Pirozzi; Davide De Marchi; Davide Inverardi; Maria A Cerruto; Nelia Amigoni; Riccardo Rizzetto; Matteo Brunelli; Roberto Iacovelli; Salvatore Siracusano; Walter Artibani
Journal:  Curr Urol       Date:  2019-07-20

Review 7.  Robot assisted lymphadenectomy in urology: pelvic, retroperitoneal and inguinal.

Authors:  Giovannalberto Pini; Surena F Matin; Nazareno Suardi; Mihir Desai; Inderbir Gill; James Porter; Robert J Stein; Rene Sotelo; Franco Gaboardi; Francesco Porpiglia
Journal:  Minerva Urol Nefrol       Date:  2016-11-08

8.  Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.

Authors:  Ning Xu; Hui-Jun Chen; Shao-Hao Chen; Xue-Yi Xue; Hong Chen; Qing-Shui Zheng; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Hai Cai; Xiong-Lin Sun
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

9.  Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.

Authors:  Qing-Shui Zheng; Shao-Hao Chen; Yu-Peng Wu; Hui-Jun Chen; Hong Chen; Yong Wei; Xiao-Dong Li; Jin-Bei Huang; Xue-Yi Xue; Ning Xu
Journal:  J Cancer       Date:  2018-02-28       Impact factor: 4.207

10.  Skin sparing mastectomy and robotic latissimus dorsi-flap reconstruction through a single incision.

Authors:  Gilles Houvenaeghel; Marie Bannier; Sandrine Rua; Julien Barrou; Mellie Heinemann; Eric Lambaudie; Monique Cohen
Journal:  World J Surg Oncol       Date:  2019-11-02       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.